tiprankstipranks
Trending News
More News >

Esperion Expands Board with New Appointment

Story Highlights
Esperion Expands Board with New Appointment

Don’t Miss TipRanks’ Half-Year Sale

Esperion ( (ESPR) ) just unveiled an announcement.

On July 1, 2025, Esperion announced the appointment of Craig Thompson, CEO of Cerevance, to its Board of Directors, expanding the board to eight members. Thompson’s extensive experience in biopharmaceutical leadership is expected to enhance Esperion’s strategic direction as it continues to innovate in cardiovascular and cardiometabolic drug development, potentially impacting its market position and stakeholder interests.

The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.

Spark’s Take on ESPR Stock

According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.

Esperion’s overall stock score reflects significant financial risks due to negative profitability and high leverage, despite strong revenue growth and positive sentiment from recent corporate events and earnings call. Technical indicators suggest potential for rebound, but valuation remains a concern.

To see Spark’s full report on ESPR stock, click here.

More about Esperion

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing oral, non-statin medicines for patients at risk of cardiovascular disease. The company is known for its FDA-approved therapies targeting elevated low-density lipoprotein cholesterol (LDL-C) and is advancing its pipeline with ATP citrate lyase inhibitors (ACLYi).

Average Trading Volume: 5,164,958

Technical Sentiment Signal: Sell

Current Market Cap: $196.9M

Learn more about ESPR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1